FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2522207921> ?p ?o ?g. }

• W2522207921 endingPage "3560" @default.
• W2522207921 startingPage "3560" @default.
• W2522207921 abstract "Abstract Cold agglutinin disease (CAD) is an autoimmune hemolytic anemia (AIHA) characterized by the presence of autoantibodies (cold agglutinins) that bind red blood cells (RBCs) and activate the classical complement pathway (CP). We have previously shown in vitro that in contrast to C5 inhibition, inhibition of the CP specific protease C1s prevents complement opsonin deposition on cold agglutinin-sensitized RBCs and protects them from phagocytosis, underscoring the necessity to block upstream CP activity (Shi et al., Blood, 2014). Based on the strong scientific rationale and nonclinical data, a Phase 1 clinical trial for TNT009, a monoclonal antibody (mAb) inhibitor of C1s, has commenced at the Medical University of Vienna, Austria. Phase 1a consists of healthy volunteer cohorts in single- and multiple-ascending dose protocols for which interim study results will be presented. In the integrated protocol design of Phase 1b, TNT009 will be dosed in patients with diseases in which pathological CP activity has been implicated, including CAD, warm AIHA and additional non-hematologic indications. In anticipation of the clinical trial, we initiated a screening campaign in Vienna to find prospective CAD patients with serological markers of anemia and hemolysis. To date, plasma and serum samples have been collected from 15 CAD patients. Serum samples from 10 patients induce robust complement activation (C3b/iC3b deposition and/or hemolysis) on AET-treated human RBCs incubated in the patient's own complement-containing serum. In contrast to isotype control (IC), 100 mcg/mL of TNT003 (mouse parental mAb of TNT009), showed near complete inhibition of patient serum mediated C3b/iC3b deposition (90 ± 4%, n = 10; p< 1 x 10-5) and hemolysis (93 ± 5 %, n = 9; p< 1 x 10-5) (Fig. 1). To further support the rationale of C1s inhibition in CAD, we asked whether serological signs of anemia and hemolysis were associated with evidence of increased in vivo CP activity in patient samples. We first examined how well experimental laboratory results agreed with standard clinical readouts. We found good concordance between patient sample induced C3 deposition on RBCs (FACS) and clinical C3 DAT scores (p< .05). Furthermore, IgM staining on RBCs incubated in patient samples (FACS) correlated well with cold agglutinin titers determined in the clinic (p < .001). Next, we observed that the extent of in vitro hemolysis correlated with C3d DAT scores (p< .05), LDH levels (p< .05), and bilirubin levels (p= .05). The agreement between the results from our in vitro patient sample-induced hemolysis assay with serologicalmarkers of complement activity, hemolysis and anemia used in the clinic suggest that our in vitro paradigm serves as a good model for in vivo complement activity in CAD patients. We then measured plasma C4 levels and CP activity in CAD serum samples (Wieslab Classical Pathway ELISA). We found that plasma C4 positively correlated with hemoglobin levels (p = .05). Additionally, we found an inverse correlation between serum CP activity and reticulocyte count (p < .05) and bilirubin levels (p = .05). These data demonstrate that in vivo consumption of the CP and its components (low CP activity, low C4) is associated with markers of anemia and hemolysis (low hemoglobin, high reticulocyte counts, high bilirubin). Finally, an emerging literature calls attention to an increased thromboembolic risk in AIHA, similar to that seen in patients with other hemolytic anemias such as paroxysmal nocturnal hemoglobinuria. We therefore measured D-dimer levels and found it significantly elevated in CAD patient plasma compared to healthy controls (p < .0001). Preliminary analyses show an inverse correlation of C4 and D-dimer in patient plasma (p < .05) suggesting that in vivo CP activity may contribute to the elevated thromboembolic risk in patients (Fig. 2). On-going analyses for other markers of thrombosis, in addition to other experimental approaches to assess the hypercoagulable state in these patients will seek to corroborate this finding. The successful identification of CAD patients with altered complement and hematological profiles provides a unique opportunity to assess proof-of-concept early in the clinical development of TNT009. Figure 1. TNT009 Parental mAb (TNT003) Inhibits CAD Serum Mediated Complement Activation on AET-Treated Human RBCs Figure 1. TNT009 Parental mAb (TNT003) Inhibits CAD Serum Mediated Complement Activation on AET-Treated Human RBCs Figure 2. Elevated D-dimer Correlates with Lower C4 Levels in CAD Patient Plasma Figure 2. Elevated D-dimer Correlates with Lower C4 Levels in CAD Patient Plasma Disclosures Jaeger: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; True North Therapeutics, Inc.: Research Funding; Hoffmann La Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Rose:True North Therapeutics, Inc.: Employment, Equity Ownership. Singh:True North Therapeutics, Inc.: Employment, Equity Ownership. Jilma:True North Therapeutics, Inc.: Consultancy, Research Funding. Gilbert:True North Therapeutics, Inc.: Employment, Equity Ownership. Panicker:True North Therapeutics, Inc.: Employment, Equity Ownership, Patents & Royalties." @default.
• W2522207921 created "2016-09-30" @default.
• W2522207921 creator A5027035462 @default.
• W2522207921 creator A5027165619 @default.
• W2522207921 creator A5036988600 @default.
• W2522207921 creator A5074348178 @default.
• W2522207921 creator A5080941679 @default.
• W2522207921 creator A5080965908 @default.
• W2522207921 creator A5091419034 @default.
• W2522207921 creator A5091600576 @default.
• W2522207921 date "2015-12-03" @default.
• W2522207921 modified "2023-09-27" @default.
• W2522207921 title "Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease" @default.
• W2522207921 doi "https://doi.org/10.1182/blood.v126.23.3560.3560" @default.
• W2522207921 hasPublicationYear "2015" @default.
• W2522207921 type Work @default.
• W2522207921 sameAs 2522207921 @default.
• W2522207921 citedByCount "1" @default.
• W2522207921 countsByYear W25222079212016 @default.
• W2522207921 crossrefType "journal-article" @default.
• W2522207921 hasAuthorship W2522207921A5027035462 @default.
• W2522207921 hasAuthorship W2522207921A5027165619 @default.
• W2522207921 hasAuthorship W2522207921A5036988600 @default.
• W2522207921 hasAuthorship W2522207921A5074348178 @default.
• W2522207921 hasAuthorship W2522207921A5080941679 @default.
• W2522207921 hasAuthorship W2522207921A5080965908 @default.
• W2522207921 hasAuthorship W2522207921A5091419034 @default.
• W2522207921 hasAuthorship W2522207921A5091600576 @default.
• W2522207921 hasBestOaLocation W25222079211 @default.
• W2522207921 hasConcept C111684460 @default.
• W2522207921 hasConcept C159654299 @default.
• W2522207921 hasConcept C189446657 @default.
• W2522207921 hasConcept C203014093 @default.
• W2522207921 hasConcept C2776175824 @default.
• W2522207921 hasConcept C2777385706 @default.
• W2522207921 hasConcept C2777884830 @default.
• W2522207921 hasConcept C2777991845 @default.
• W2522207921 hasConcept C2779902561 @default.
• W2522207921 hasConcept C542903549 @default.
• W2522207921 hasConcept C71924100 @default.
• W2522207921 hasConcept C86803240 @default.
• W2522207921 hasConceptScore W2522207921C111684460 @default.
• W2522207921 hasConceptScore W2522207921C159654299 @default.
• W2522207921 hasConceptScore W2522207921C189446657 @default.
• W2522207921 hasConceptScore W2522207921C203014093 @default.
• W2522207921 hasConceptScore W2522207921C2776175824 @default.
• W2522207921 hasConceptScore W2522207921C2777385706 @default.
• W2522207921 hasConceptScore W2522207921C2777884830 @default.
• W2522207921 hasConceptScore W2522207921C2777991845 @default.
• W2522207921 hasConceptScore W2522207921C2779902561 @default.
• W2522207921 hasConceptScore W2522207921C542903549 @default.
• W2522207921 hasConceptScore W2522207921C71924100 @default.
• W2522207921 hasConceptScore W2522207921C86803240 @default.
• W2522207921 hasIssue "23" @default.
• W2522207921 hasLocation W25222079211 @default.
• W2522207921 hasOpenAccess W2522207921 @default.
• W2522207921 hasPrimaryLocation W25222079211 @default.
• W2522207921 hasRelatedWork W1931252031 @default.
• W2522207921 hasRelatedWork W2201952665 @default.
• W2522207921 hasRelatedWork W2259036662 @default.
• W2522207921 hasRelatedWork W2273784326 @default.
• W2522207921 hasRelatedWork W2522207921 @default.
• W2522207921 hasRelatedWork W2797165009 @default.
• W2522207921 hasRelatedWork W2916542983 @default.
• W2522207921 hasRelatedWork W3214474180 @default.
• W2522207921 hasRelatedWork W4220944640 @default.
• W2522207921 hasRelatedWork W4241666147 @default.
• W2522207921 hasVolume "126" @default.
• W2522207921 isParatext "false" @default.
• W2522207921 isRetracted "false" @default.
• W2522207921 magId "2522207921" @default.
• W2522207921 workType "article" @default.